System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Paul Nghiem is an expert in Oncology at Fred Hutchinson Cancer Research Center (United States). As of October 2026, ScienceLeadR ranks Paul Nghiem in the top 1% of experts worldwide for Carcinoma. Paul Nghiem has authored 383 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 1 of them ongoing. SLR score: 2,668 (community average: 125). How the SLR is computed.

LeadR Profile

Paul Nghiem Fred Hutchinson Cancer Research Center United States
2 668 ScienceLeadR Reputation 2668

Unlock

Register Login
Network Map

Oncology

Subspecialties: Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2006 - 2026
Source: PubMed

University of Washington

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 383

Citations

Citations: 20 559 1st author: 25 Last author: 167 Unique author: 8

Main journals

J Invest Dermatol 67
J Am Acad Dermatol 27
J Clin Oncol 27
J Immunother Cancer 20
Int J Radiat Oncol Biol Phys 16

Best Journals

J Clin Oncol 10
Ann Oncol 3
N Engl J Med 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Perspectives on 10 years of Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: A Podcast.
PMID 42844522 — cells, merkel cells, neoplasms, immune checkpoint inhibitors, therapeutics, carcinoma, merkel cell		Target Oncol20260
ATR inhibition induces NF-κB-dependent immunogenicity in Merkel cell carcinoma independent of cGAS-STING.
PMID 42834086 — cells, merkel cells, macrophages, neoplasms, therapeutics, carcinoma, merkel cell		NPJ Precis Oncol20260
Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma.
PMID 42715345 — interferon-gamma, cells, merkel cells, neoplasms, therapeutics, t-lymphocytes, carcinoma, merkel cell		Sci Transl Med20260
Minimal Efficacy of Single-Agent Anti-PD-(L)1 Re-Exposure in Anti-PD-(L)1-Refractory Merkel Cell Carcinoma: A Retrospective Cohort Study of 16 Patients.
PMID 42649984 — cells, merkel cells, cohort studies, immunotherapy, immune checkpoint inhibitors, therapeutics, carcinoma, merkel cell		Cancers (Basel)20261
One dose of adjuvant 8 Gray postoperative radiotherapy for Merkel cell carcinoma excised with narrow margins: low toxicity and comparable efficacy to conventional radiotherapy.
PMID 42476365 — radiotherapy, cells, quality of life, merkel cells, risk factors, dermatology, carcinoma, merkel cell		J Am Acad Dermatol20260

Clinical Studies 6

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 4
Phase 1 1
Phase 1/Phase 2 1

By status:

Completed 4
Active not recruiting 1
Terminated 1

By type:

Interventional 6

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 0
multicentricup10 4

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer MATRiX Trial
NCT05947500 — skin, cells, research design, merkel cells, safety, blood, pharmaceutical preparations, tomography, positron-emission tomography, neoplasms, magnetic resonance imaging, biopsy, positron emission tomography computed tomography, enzymes, specimen handling, therapeutics, dna, carcinoma, merkel cell, skin neoplasms, carcinoma		Phase 2Active not recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS